How do you pack 20 years of ADC learnings into one company? Tubulis has $63M more to answer that
More than two decades have passed since the first antibody-drug conjugate went on the market. But according to a biotech startup out of Germany, the space is really just beginning to flourish.
And if Tubulis gets its way, it will play a big part in designing the ADCs that will be deployed in cancer treatments of tomorrow.
Andera Partners led a new $63 million (€60 million) into the company, which brought new investors Evotec and Fund+ into the syndicate, joining Bayern Kapital, BioMedPartners, coparion, High-Tech Gründerfonds, OCCIDENT and Seventure Partners.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.